top of page
On the Scales

Approximately 70% of American adults have obesity or are overweight, and many of those overweight have a weight-related condition. Losing 5% to 10% of body weight through diet and exercise has been associated with a reduced risk of cardiovascular disease in adults with obesity or overweight.

Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes.

In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need.

Often due to metabolic reasons or time limitations this weight loss is difficult to achieve just with diet and exercise alone.  This is where the newer line of medications approved by the FDA can help.  These products are in the class of GLP-1 agonists and include several products.  We are excited to offer some of them to our patients.  Semaglutide and Tirzepatide are two compounded versions of these medications and have been shown to help patients in their pursuit of weight loss.  These products work to help decrease appetite and therefore caloric consumption.  This coupled with diet and exercise can help patients achieve their desired goals.

These medications can come with side effects which are usually mild and transitory but every person has their own experience.  If this is something you are interested in please contact us to find out more.

Obesity and Weight Loss

Semaglutide Overview

Intro To Our Weight Loss Program


Wegovy® was FDA approved as a weight loss drug after it’s predecessor, semaglutide (Ozempic®) was noted to lead to weight loss in diabetic patients.

Semaglutide works via mimicking (agonist) GLP-1 (glucagon like peptide) to increase insulin secretion to increase sugar metabolism, but also signals your brain to decrease appetite.

Although there are going to be several competitors on the market soon based on this concept, right now, semaglutide has the highest risk benefit ratio of all weight loss drugs.





bottom of page